# A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

> **NCT03463928** · PHASE1 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- B Cell Leukemia

## Interventions

- **BIOLOGICAL:** donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT

## Key facts

- **NCT ID:** NCT03463928
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-08
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463928, "A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03463928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*